Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Zoom Video Communications, Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Zoom Video Communications, Inc. trades at $97.74 (market cap $27.62B). The key difference: Zoom Video Communications, Inc. is far larger — about 2.2× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Zoom Video Communications, Inc. for 92 Days on average.
| HALO | ZM | |
|---|---|---|
Market Cap | $12.58B | $27.62B |
Volume | 2,179,278 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $115.22 | $111.88 |
52-Week Low | $61.63 | $72.72 |
Typical Hold Time | 1 Days | 92 Days |
Enterprise Value | $14.49B | $20.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoom Communications (ZM) trades at $94.67, showing minimal daily movement (-0.11%). The stock maintains a bullish technical outlook with strong moving average signals, though oscillators indicate neutral momentum. Fundamentally, ZM demonstrates robust profitability with 77.3% gross margins and 65.19% net income margin, supported by recent earnings beats. The company continues to innovate with AI-powered revenue solutions and maintains significant institutional interest.
With a consensus price target of $118.08 offering 25% upside potential, ZM presents growth opportunities driven by AI integration and strong financial metrics. However, risks include competitive pressures in the communication software space and reliance on international sales growth. The mixed analyst sentiment (38.78% buy vs 55.1% hold) suggests cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
